Picard Medical, Inc.
PMI
Positions held
Your positionsPMI isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $22.64M | Enterprise value | $24.18M | Trailing P/E | — | Forward P/E | -2.15 |
| PEG | — | Price / book | 11.59 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | 38.6% | Earnings growth | — | Gross margin | 18.6% | Operating margin | -1.6% |
| Profit margin | 0.0% | ROE | — | ROA | -93.6% | Debt / equity | 0.92 |
| Current ratio | 1.02 | Free cash flow | -$22.79M | Analyst recommendation | none | Mean target | — |
| 52w high | $684.00 | 52w low | $2.65 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $3.0M | $1.1M | $1.0M | $1.2M | $2.1M | — |
| Op margin | -156.7% | -392.3% | -297.6% | -293.8% | -165.2% | — |
| Net income | -$5.7M | -$7.6M | -$4.3M | -$10.4M | -$6.7M | — |
| Gross margin | 20.9% | 23.9% | 40.7% | -11.0% | -6.0% | — |
| Gross profit | $0.6M | $0.3M | $0.4M | -$0.1M | -$0.1M | — |
| Operating income | -$4.6M | -$4.5M | -$3.0M | -$3.5M | -$3.5M | — |
- Revenue +157% vs prior quarter ($3.0M vs $1.1M).
- Gross margin 20.9% (was 23.9% prior quarter).
- Operating margin expanded to -156.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $4.9M | $4.4M | $5.0M | $4.1M |
| Op margin | -268.4% | -312.3% | -307.4% | -269.1% |
| Net income | -$27.0M | -$21.1M | -$15.6M | -$11.2M |
| Gross margin | -4.1% | -2.6% | -45.8% | -121.3% |
| Gross profit | -$0.2M | -$0.1M | -$2.3M | -$5.0M |
| Operating income | -$13.3M | -$13.7M | -$15.5M | -$11.1M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-01 · Philip Morris International to Host Webcast of Fireside Chat Session at Barclays Global Consumer Conference
2026-08-24 · Top Premarket Gainers
2026-08-24 · Philip Morris International Announces Contract Manufacturing Collaboration with Altria
2026-08-24 · Picard Medical Shares Soar After Quarterly Revenue Beats Forecasts
2026-08-21 · FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review
2026-08-19 · Picard Medical Reports Second Quarter 2026 Financial Results
2026-08-13 · Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates
2026-07-31 · Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026
2026-07-27 · Picard Medical / SynCardia to Present Next-Generation Emperor Total Artificial Heart Technology at IEEE EMBC 2026
2026-07-27 · Picard Medical Says NYSE American Accepts Listing Compliance Plan
2026-07-27 · PMI U.S. Opens $1.2 Billion Aurora Campus, Strengthening U.S. Manufacturing and Export Capabilities
2026-07-27 · Picard Medical Receives NYSE American Acceptance of Compliance Plan
Price (daily)
Full chart · RSI · MACD · patterns